» Articles » PMID: 34677244

Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2021 Oct 22
PMID 34677244
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

From a Canadian perspective, there has been a limited discussion on the frontline management of young, fit patients with chronic lymphocytic leukemia (CLL). The prevalence of this population ranges between 2 and 22 per 100,000 persons in Canada and varies by region. Until recently, fixed-duration fludarabine-based chemoimmunotherapy (CIT) was the primary treatment option in Canada for this patient population. The ECOG1912 trial has since demonstrated that ibrutinib and rituximab therapy are as effective as fludarabine-cyclophosphamide-rituximab (FCR) in this population. The ALLIANCE trial showed that rituximab added no incremental benefit to ibrutinib. Canadian payors and physicians adopted ibrutinib monotherapy as the CLL standard of care, even in the young, fit population, although frontline ibrutinib therapy is often reimbursed by provincial public drug plans only in patients with high-risk disease or those who are unfit to receive fludarabine. Young, fit patients with CLL and their physicians may now choose between continuous ibrutinib monotherapy and fixed-duration CIT with FCR. Factors affecting this choice include patient preference and the short- and long-term toxicity profiles of both regimens, and a risk-based algorithm is provided. As new continuous-therapy options enter the market, all treatment choices present benefits and risks that must be communicated to the patient.

Citing Articles

Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia.

Vu M, Degeling K, Thompson E, Blombery P, Westerman D, IJzerman M Appl Health Econ Health Policy. 2023; 22(1):107-122.

PMID: 37608228 PMC: 10761538. DOI: 10.1007/s40258-023-00826-4.

References
1.
Andreani G, Carra G, Lingua M, Maffeo B, Brancaccio M, Taulli R . Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets. Cancers (Basel). 2020; 12(3). PMC: 7139490. DOI: 10.3390/cancers12030629. View

2.
Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291. PMC: 8151619. DOI: 10.1016/S0140-6736(20)30262-2. View

3.
Rozman C, Montserrat E . Chronic lymphocytic leukemia. N Engl J Med. 1995; 333(16):1052-7. DOI: 10.1056/NEJM199510193331606. View

4.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L . Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2018; 20(1):43-56. DOI: 10.1016/S1470-2045(18)30788-5. View

5.
Shustik C, Bence-Bruckler I, Delage R, Owen C, Toze C, Coutre S . Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Ann Hematol. 2017; 96(7):1185-1196. PMC: 5486803. DOI: 10.1007/s00277-017-2982-1. View